Intel, TTM Technologies, and GE Aerospace stocks experienced declines on Monday, while Argenx stock saw a significant rise and Rocket Lab also had notable movement. These companies exhibited diverse performance in the stock market.

Shares of Argenx SE jumped significantly following the European biotech company's announcement of another large, successful trial for its blockbuster autoimmune drug, Vyvgart.

Argenx SE is preparing to present evidence of its drug Vyvgart's effectiveness across a wider spectrum of autoimmune diseases, potentially expanding its therapeutic applications.

argenx has committed $2.2 billion to a vitiligo breakthrough through a deal with Forte Biosciences, with implications for both companies' stock performance.

Argenx has agreed to acquire Forte Biosciences for $2.2 billion, a move aimed at strengthening its pipeline of autoimmune drugs with the addition of FB102.

argenx reported a 60% increase in VYVGART sales as the company approaches key pipeline readouts for its pharmaceutical products.

Argenx has secured FDA approval to broaden the label for its drug Vyvgart, allowing for its use in a wider range of patients with myasthenia gravis.

Yahoo Finance reports on the reasons behind Argenx SE's decline in performance during the first quarter.

Argenx (ARGX) announced a 90% increase in net product sales to $4.2 billion in 2025, achieving its first annual profit, signaling strong growth and financial milestones for the company.

argenx SE reported its latest financial figures, with GAAP EPS of $8.02, beating estimates by $1.70, while revenue of $1.29 billion missed expectations by $10 million.

Argenx shares have risen significantly following positive results from a Phase 3 study of efgartigimod in an autoimmune myositis trial. The promising data indicates potential for the drug in treating the condition.

argenx has reported positive topline results from its Phase 3 ALKIVIA trial, evaluating efgartigimod for the treatment of autoimmune myositis.

A review of significant business deals that occurred this week, featuring companies such as Ambarella, MarketAxess, argenx SE, and TransDigm.

Argenx has signed an agreement to acquire Forte Biosciences in a deal valued at $2.2 billion.

Argenx has announced its intention to acquire Forte in a $2.2 billion deal. The acquisition is focused on obtaining a 'differentiated' immune drug.

Evercore ISI has increased its price target for argenx (ARGX) stock.

Argenx SE reported GAAP EPS of $5.52, beating estimates, while its revenue of $1.3 billion missed expectations. Separately, Forrester Research announced non-GAAP EPS of -$0.04, missing estimates, though its revenue of $85.5 million surpassed projections.

The outlook for Argenx (ARGX) has improved following the expansion of its pipeline for autoimmune diseases.

Analysts have expressed varying opinions regarding the stock performance of Argenx SE (ARGX).

The Artisan Mid Cap Fund has expressed continued confidence in Argenx’s (ARGX) product, VYVGART, indicating a positive outlook on the investment.

Argenx has made progress as its drug, Vyvgart, successfully met key trial endpoints for the treatment of autoimmune myositis.

Hedge funds are showing a preference for argenx (ARGX) over Forte Biosciences, Inc. (FBRX) after argenx agreed to acquire Forte Biosciences.

Charts reveal significant price movement in Forte Biosciences stock, occurring ahead of Argenx’s anticipated acquisition announcement.

Argenx has signed an agreement to acquire Forte Biosciences in a deal valued at $2.2 billion.

Several companies, including U.S. Century Bank, Selective Insurance, and SS&C, have reported their Q2 earnings, with many exceeding analyst expectations for EPS and revenue. However, some, like Boston Beer and Marten Transport, missed their targets.

A financial analysis article evaluates argenx SE (ARGX) to determine if it is among the most promising biotech stocks for investment.

Key highlights from Argenx's fourth-quarter earnings call have been released.